Results 81 to 90 of about 688 (142)

Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift. [PDF]

Cureus, 2023
Motlani G, Motlani V, Acharya N, Dave A, Pamnani S, Somyani D, Agrawal S.   +6 more
europepmc   +1 more source

Quality of life and Satisfaction With Ospemifene for Treating Vulvovaginal Atrophy in Breast Cancer Survivors: Six-Month Results From the PatiEnt SatisfactiON StudY (PEONY)

Objective: Breast cancer (BC) survivors often experience vulvovaginal atrophy (VVA) due to endocrine therapies, affecting quality of life (QoL) and well-being. We aimed to evaluate impact of ospemifene treatment in postmenopausal women with history of BC
Bounous, Valentina E, Bounous V. E., Villa P., Guida M., Di Lelio A., Meriggiola M. C., Cassani C., Amar I. D., Trionfera V., Franchi D., Nappi R. E., Cova L., Graziano G.   +12 more
core   +1 more source

Efficacy of ospemifene on female sexual function in patients with vulvovaginal atrophy and breast cancer history: a randomized, double-blind, controlled clinical trial

, 2019
Background: Vulvovaginal atrophy (VVA) is a condition affecting about 50% of postmenopausal women with a negative repercussion on their sexual function and quality of life when its symptoms are moderate to severe.
Roura Coll, Carla
core   +1 more source

Urinary manifestations of genitourinary syndrome of menopause: a review of the pathophysiology, clinical presentation, and management. [PDF]

Gynecol Pelvic Med
Saad JC, Brandon CA.
europepmc   +1 more source

Selective oestrogen receptor modulators and Alzheimer´s disease: a real-world pharmacovigilance study. [PDF]

Eur J Clin Pharmacol
Yuste MT, Badillo E, Galecio JS, Marín P.   +3 more
europepmc   +1 more source

Treatment of vulvovaginal atrophy is associated with high levels of satisfaction and improves symptom severity and patient-reported outcomes: 12-month results of the PatieEnt satisfactiON studY (PEONY)

Objective: – To evaluate whether the benefits demonstrated after 6 months of treating vulvovaginal atrophy (VVA) with ospemifene and local vaginal estrogen therapy (LET) were maintained after 12 months.
Meriggiola, Maria Cristina, Puglielli, Cristina, Nicolucci, Antonio, Nappi, Rossella E, Simoncini, Tommaso, Luisi, Stefano, Villa, Paola, Stomati, Massimo, Di Paolantonio, Tiziana, Marsini, Silvia, Cagnacci, Angelo, Lami, Alessandra   +11 more
core   +1 more source

Hormone therapy use and cancer survivorship. [PDF]

Menopause
Christmas M.
europepmc   +1 more source

A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors. [PDF]

Post Reprod Health, 2023
Hussain I, Talaulikar VS.
europepmc   +1 more source

Reproductive Longevity: Innovative Approaches Beyond Hormone Replacement Therapy. [PDF]

Medicina (Kaunas)
Jugulytė N, Bartkevičienė D.
europepmc   +1 more source

Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and Ospemifene. [PDF]

J Menopausal Med
Pennacchini E, Dall'Alba R, Iapaolo S, Marinelli M, Palazzetti PL, Zullo MA, Cervigni M, Morciano A, Campanella L, Ferraresi B, Schiavi MC.   +10 more
europepmc   +1 more source